Small Pharma to Participate in the PSYCH Symposium: London May 11, 2022
May 5th, 2022 – Small Pharma will participate in the PSYCH Symposium: London 2022 –…
Check out the latest news, press releases, events and insights or delve into all the content on specific topic areas such as DMT.
May 5th, 2022 – Small Pharma will participate in the PSYCH Symposium: London 2022 –…
April 27, 2022 – Small Pharma Inc. will present live at the KCSA Psychedelics Virtual…
DMT, short for N, N-Dimethyltryptamine, is a naturally-occurring, fast-acting psychoactive molecule. Also described as the…
James Halifax, Psychedelic Spotlight writer and their resident psychedelic investor, recently covered his 5 most…
Gail Dutton of BioSpace.com, a leading online biotechnology source for breaking industry news and expert analysis,…
View Small Pharma’s Fireside Chat Webcast from the 34th Annual Roth Conference Monday, March 14 at 3:30…
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical…
Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT Small Pharma is…
Small Pharma is pleased to announce its attendance at the PSYCH SYMPOSIUM: London 2022. Guest…
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic…
We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.
With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.